Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total transaction of $78,297.48. Following the transaction, the director now directly owns 7,109,875 shares in the company, valued at $48,631,545. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.27, for a total value of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.12, for a total value of $81,502.64.
• On Tuesday, August 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.82, for a total transaction of $78,068.54.
• On Tuesday, July 23rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.48, for a total value of $97,070.56.
• On Tuesday, July 9th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.32, for a total transaction of $83,792.04.
• On Tuesday, June 25th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total transaction of $108,860.97.

Recursion Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ:RXRX opened at $6.80 on Friday. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -4.25 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a one year low of $4.97 and a one year high of $15.74. The firm has a fifty day moving average price of $7.18 and a two-hundred day moving average price of $8.41. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. Recursion Pharmaceuticals’s quarterly revenue was up 30.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.38) EPS. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on RXRX. Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group cut their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, KeyCorp dropped their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of RXRX. Mubadala Investment Co PJSC purchased a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $128,041,000. ARK Investment Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 14.5% in the 2nd quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after buying an additional 3,555,357 shares during the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $34,825,000. Baillie Gifford & Co. lifted its holdings in shares of Recursion Pharmaceuticals by 10.5% during the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after acquiring an additional 2,522,132 shares during the last quarter. Finally, Kinnevik AB publ grew its position in Recursion Pharmaceuticals by 14.4% in the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after acquiring an additional 1,500,000 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.